Landscape Capital Management L.L.C. Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Landscape Capital Management L.L.C. bought a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,913 shares of the biopharmaceutical company’s stock, valued at approximately $141,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after purchasing an additional 436,911 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Emergent BioSolutions by 22.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares during the last quarter. Tidal Investments LLC bought a new stake in shares of Emergent BioSolutions during the first quarter valued at approximately $34,000. Cetera Advisors LLC purchased a new position in Emergent BioSolutions in the 1st quarter worth approximately $428,000. Finally, CWM LLC raised its holdings in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on EBS. Rodman & Renshaw reiterated a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Benchmark lifted their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Stock Up 4.1 %

Shares of Emergent BioSolutions stock opened at $9.87 on Tuesday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a twelve month low of $1.42 and a twelve month high of $15.10. The company has a market cap of $534.80 million, a price-to-earnings ratio of -2.47 and a beta of 1.57. The company’s 50 day moving average is $8.79 and its 200 day moving average is $8.27.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.